NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma
Authors:
- 1 December 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (23) , 5830-5840
Abstract
Purpose: Only one chemical class of topoisomerase I (TOP1) inhibitors is FDA approved, the camptothecins with irinotecan and topotecan widely used. Because of their limitations (chemical instability, drug efflux-mediated resistance, and diarrhea), novel TOP1 inhibitors are warranted. Indenoisoquinoline non-camptothecin topoisomerase I (TOP1) inhibitors overcome chemical instability and drug resistance that limit camptothecin use. Three indenoisoquinolines, LMP400 (indotecan), LMP776 (indimitecan), and LMP744, were examined in a phase I study for lymphoma-bearing dogs to evaluate differential efficacy, pharmacodynamics, toxicology, and pharmacokinetics. Experimental Design: Eighty-four client-owned dogs with lymphomas were enrolled in dose-escalation cohorts for each indenoisoquinoline, with an expansion phase for LMP744. Efficacy, tolerability, pharmacokinetics, and target engagement were determined. Results: The MTDs were 17.5 mg/m2 for LMP 776 and 100 mg/m2 for LMP744; bone marrow toxicity was dose-limiting; up to 65 mg/m2 LMP400 was well-tolerated and MTD was not reached. None of the drugs induced notable diarrhea. Sustained tumor accumulation was observed for LMP744; γH2AX induction was demonstrated in tumors 2 and 6 hours after treatment; a decrease in TOP1 protein was observed in most lymphoma samples across all compounds and dose levels, which is consistent with the fact that tumor response was also observed at low doses LMP744. Objective responses were documented for all indenoisoquinolines; efficacy (13/19 dogs) was greatest for LMP744. Conclusions: These results demonstrate proof-of-mechanism for indenoisoquinoline TOP1 inhibitors supporting their further clinical development. They also highlight the value of the NCI Comparative Oncology Program (https://ccr.cancer.gov/Comparative-Oncology-Program) for evaluating novel therapies in immunocompetent pets with cancers.Keywords
All Related Versions
Funding Information
- NIH (Z01-BC006161)
- NCI (HHSN261201100015C, HHSN261200422002C, and HHSN261201100027C)
This publication has 34 references indexed in Scilit:
- Veterinary cooperative oncology group – common terminology criteria for adverse events (VCOG‐CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1Veterinary and Comparative Oncology, 2016
- Roles of eukaryotic topoisomerases in transcription, replication and genomic stabilityNature Reviews Molecular Cell Biology, 2016
- Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2016
- Interfacial inhibitors: targeting macromolecular complexesNature Reviews Drug Discovery, 2011
- Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a veterinary cooperative oncology group (VCOG) consensus documentVeterinary and Comparative Oncology, 2010
- Liquid chromatography–tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776Journal of Pharmaceutical and Biomedical Analysis, 2010
- γH2AX and cancerNature Reviews Cancer, 2008
- The mechanism of topoisomerase I poisoning by a camptothecin analogProceedings of the National Academy of Sciences, 2002
- Characterisation and Clinical Management of CPT-11 (Irinotecan)-induced Adverse Events: The European PerspectiveEuropean Journal of Cancer, 1996
- The structural basis of camptothecin interactions with human serum albumin: impact on drug stabilityJournal of Medicinal Chemistry, 1994